Atea Pharmaceuticals, Inc.AVIRNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-13.15%
↑ 82% above average
Average (26q)
-72.80%
Historical baseline
Range
High:515.45%
Low:-1931.97%
Volatility
-3361.8%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -13.15% |
| Q2 2025 | -8.43% |
| Q1 2025 | -2.17% |
| Q4 2024 | -7.68% |
| Q3 2024 | 23.13% |
| Q2 2024 | 35.85% |
| Q1 2024 | -61.29% |
| Q4 2023 | -18.17% |
| Q3 2023 | -17.60% |
| Q2 2023 | 20.54% |
| Q1 2023 | -3.01% |
| Q4 2022 | -326.87% |
| Q3 2022 | 74.26% |
| Q2 2022 | 25.53% |
| Q1 2022 | -135.92% |
| Q4 2021 | 515.45% |
| Q3 2021 | -1931.97% |
| Q2 2021 | -94.99% |
| Q1 2021 | 48.69% |
| Q4 2020 | 217.22% |
| Q3 2020 | -76.34% |
| Q2 2020 | -150.58% |
| Q1 2020 | 14.33% |
| Q4 2019 | -28.17% |
| Q3 2019 | -2.19% |
| Q2 2019 | -62.06% |
| Q1 2019 | 0.00% |